Recombinant vaccines and the development of new vaccine strategies

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 12, 2012, Pages 1102-1111

  Nascimento, I P ^a   Leite, L C C ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

Human vaccines; Recombinant vaccines; Safety; Vectors for immunization

Indexed keywords

BACTERIAL VACCINE; BACTERIAL VECTOR; BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; LISTERIOLYSIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR; VIRUS VACCINE; VIRUS VECTOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TH1 CELL; TH2 CELL; TUBERCULOSIS; VACCINATION;

BACTERIAL VACCINES; BIOTECHNOLOGY; GENETIC VECTORS; HUMANS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84872324423     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500142     Document Type: Review

References (70)

1. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20: 63-75.
2. Ada G. Overview of vaccines and vaccination. Mol Biotech- nol 2005; 29: 255-272.
3. Robinson HL, Amara RR. T cell vaccines for microbial infec- tions. Nat Med 2005; 11: S25-S32.
4. Lemaire D, Barbosa T, Rihet P. Coping with genetic diversity: the contribution of pathogen and human genomics to modern vaccinology. Braz J Med Biol Res 2012; 45: 376-385.
5. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010; 33: 530-541.
6. Cardoso FC, Pacifco RN, Mortara RA, Oliveira SC. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. Clin Exp Immunol 2006; 144: 382-391.
7. Hansson M, Nygren PA, Stahl S. Design and production of recombinant subunit vaccines. Biotechnol Appl Biochem 2000; 32 (Part 2): 95-107.
8. Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev Biol 2005; 121: 153-163.
9. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008; 364: 272-280.
10. Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol 2010; 58: 288-295.
11. Dertzbaugh MT. Genetically engineered vaccines: an over-view. Plasmid 1998; 39: 100-113.
12. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs 1998; 10: 137-158.
13. Govan VA. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Ther Clin Risk Manag 2008; 4: 65-70.
14. Perez O, Batista-Duharte A, Gonzalez E, Zayas C, Balboa J, Cuello M, et al. Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations. Braz J Med Biol Res 2012; 45: 681-692.
15. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 infammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453: 1122-1126.
16. Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM. Re- cent advances with recombinant bacterial vaccine vectors. Mol Med Today 2000; 6: 66-71.
17. Curtiss R III, Xin W, Li Y, Kong W, Wanda SY, Gunn B, et al. New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit Rev Immunol 2010; 30: 255-270.
18. Bastos RG, Borsuk S, Seixas FK, Dellagostin OA. Recombinant Mycobacterium bovis BCG. Vaccine 2009; 27: 6495-6503.
19. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011; 23: 377-382.
20. Bruhn KW, Craft N, Miller JF. Listeria as a vaccine vector. Microbes Infect 2007; 9: 1226-1235.
21. Roland KL, Tinge SA, Killeen K P, Kochi SK. Recent advances in the development of live, attenuated bacterial vectors. Curr Opin Mol Ther 2005; 7: 62-72.
22. Detmer A, Glenting J. Live bacterial vaccines - a review and identification of potential hazards. Microb Cell Fact 2006; 5: 23.
23. Galen JE, Pasetti MF, Tennant S, Ruiz-Olvera P, Sztein MB, Levine MM. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol 2009; 87: 400-412.
24. Stover CK, de la Cruz V, Fuerst TR, Burlein JE, Benson LA, Bennett LT, et al. New use of BCG for recombinant vaccines. Nature 1991; 351: 456-460.
25. Lim EM, Lagranderie M, Le Grand R, Rauzier J, Gheorghiu M, Gicquel B, et al. Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. AIDS Res Hum Retro- viruses 1997; 13: 1573-1581.
26. Nascimento IP, Dias WO, Quintilio W, Hsu T, Jacobs WR Jr, Leite LC. Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: protection against Bordetella pertussis challenge in neonates. Vaccine 2009; 27: 7346-7351.
27. Nascimento IP, Dias WO, Mazzantini RP, Miyaji EN, Gam- berini M, Quintilio W, et al. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect Immun 2000; 68: 4877-4883.
28. Triccas JA. Recombinant BCG as a vaccine vehicle to protect against tuberculosis. Bioeng Bugs 2010; 1: 110-115.
29. Kaufmann SH, Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Current Opinion in Biotechnology. http://www.ncbi.nlm.nih.gov/pubmed/22483201.
30. Nicol MP, Grobler LA. MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther 2010; 12: 124-134.
31. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser EA, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005; 115: 2472-2479.
32. Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008; 372: 164-175.
33. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci U S A 1996; 93: 934-939.
34. McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 2011; 366: 2782-2789.
35. Kagina BMN, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns. http:// www.ncbi.nlm.nih.gov/pubmed/20558627.
36. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006; 24: 3408-3419.
37. Waters WR, Palmer MV, Nonnecke BJ, Thacker TC, Scherer CF, Estes DM, et al. Efficacy and immunogenicity of My- cobacterium bovis DeltaRD1 against aerosol i infection in neonatal calves. Vaccine 2009; 27: 1201-1209.
38. Pincha M, Sundarasetty BS, Stripecke R. Lentiviral vectors for immunization: an inflammatory field. Expert Rev Vaccines 2010; 9: 309-321.
39. Draper SJ, Heeney JL. Viruses as vaccine vectors for in- fectious diseases and cancer. Nat Rev Microbiol 2010; 8: 62-73.
40. Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 2004; 15: 506-512.
41. Limbach KJ, Richie TL. Viral vectors in malaria vaccine development. Parasite Immunol 2009; 31: 501-519.
42. Abaitua F, Rodriguez JR, Garzon A, Rodriguez D, Esteban M. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 2006; 116: 11-20.
43. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011; 11: 633- 640.
44. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616-629.
45. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 2010; 5: 386-390.
46. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415: 331-335.
47. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication- incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008; 46: 1769-1781.
48. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
49. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 2011; 11: 189-217.
50. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
51. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
52. Oliveira SC, Rosinha GM, de-Brito CF, Fonseca CT, Afonso RR, Costa MC, et al. Immunological properties of gene vaccines delivered by different routes. Braz J Med Biol Res 1999; 32: 207-214.
53. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci U S A 1990; 87: 9568-9572.
54. de Oliveira CI, Nascimento IP, Barral A, Soto M, Barral-Netto M. Challenges and perspectives in vaccination against leishmaniasis. Parasitol Int 2009; 58: 319-324.
55. Belakova J, Horynova M, Krupka M, Weigl E, Raska M. DNA vaccines: are they still just a powerful tool for the future? Arch Immunol Ther Exp 2007; 55: 387-398.
56. Lima KM, dos Santos SA, Santos RR, Brandao IT, Rodrigues JM Jr, Silva CL. Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo. Vaccine 2003; 22: 49-56.
57. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012; 11: 189-209.
58. Chiarella P, Fazio VM, Signori E. Application of electropora- tion in DNA vaccination protocols. http://www.ncbi.nlm.nih.gov/pubmed/20504275.
59. Radosevic K, Rodriguez A, Lemckert A, Goudsmit J. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev Vaccines 2009; 8: 577-592.
60. Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Sci- ence 1992; 255: 456-459.
61. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines co expressed in recombinant fowl pox virus. J Virol 1994; 68: 8125-8130.
62. Ranasinghe C, Ramshaw IA. Genetic heterologous prime- boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev Vaccines 2009; 8: 1171-1181.
63. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997; 11 (Suppl A): S127-S137.
64. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modifed vaccinia virus Ankara. Nat Med 1998; 4: 397-402.
65. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkung- wal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-2220.
66. Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodefciency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011; 29: 6191-6218.
67. McShane H, Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect 2005; 7: 962-967.
68. Woodland DL. Jump-starting the immune system: prime- boosting comes of age. Trends Immunol 2004; 25: 98-104.
69. Dominguez MR, Silveira EL, de Vasconcelos JR, de Alencar BC, Machado AV, Bruna-Romero O, et al. Subdominant/ cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite. PLoS One 2011; 6: e22011.
70. Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveck- zy CJ, Ramshaw IA. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol 2002; 14: 31-37.